Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

121. Association between use of systematic reviews and national policy recommendations on screening newborn babies for rare diseases: systematic review and meta-analysis.

Association between use of systematic reviews and national policy recommendations on screening newborn babies for rare diseases: systematic review and meta-analysis. OBJECTIVE: To understand whether international differences in recommendations of whether to screen for rare diseases using the newborn blood spot test might in part be explained by use of systematic review methods. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Website searches of 26 national screening organisations (...) . ELIGIBILITY CRITERIA FOR STUDY SELECTION: Journal articles, papers, legal documents, presentations, conference abstracts, or reports relating to a national recommendation on whether to screen for any condition using the newborn blood spot test, with no restrictions on date or language. DATA EXTRACTION: Two reviewers independently assessed whether the recommendation for or against screening included systematic reviews, and data on test accuracy, benefits of early detection, and potential harms

BMJ2018 Full Text: Link to full Text with Trip Pro

122. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. Importance: In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history (...) of prostate cancer have an increased risk of prostate cancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models

JAMA2018

123. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Prostate cancer is the second leading cause of cancer death among US men. Objective: To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force. Data Sources: Searches of PubMed (...) , EMBASE, Web of Science, and Cochrane Registries and Databases from July 1, 2011, through July 15, 2017, with a surveillance search on February 1, 2018. Study Selection: English-language reports of randomized clinical trials (RCTs) of screening; cohort studies reporting harms; RCTs and cohort studies of active localized cancer treatments vs conservative approaches (eg, active surveillance, watchful waiting); external validations of prebiopsy risk calculators to identify aggressive cancers. Data

JAMA2018

124. Screening of Esophageal Varices by Noninvasive Means in Chronic Liver Disease

Screening of Esophageal Varices by Noninvasive Means in Chronic Liver Disease 29963456 2018 11 14 2231-5047 8 1 2018 Jan-Jun Euroasian journal of hepato-gastroenterology Euroasian J Hepatogastroenterol Screening of Esophageal Varices by Noninvasive Means in Chronic Liver Disease. 18-22 10.5005/jp-journals-10018-1252 Noninvasive assessment of esophageal varices (EV) decreases the medical and financial burden related to screening and helps in the management of patients with chronic liver diseases (...) (CLDs). In this study, our aim was to assess the utility of the platelet count/spleen diameter index for the noninvasive evaluation of EV. In this cross-sectional observational study, a total of 100 CLD patients underwent screening endoscopy for EV in Medicine and Gastroenterology Department, Sylhet MAG Osmani Medical College Hospital, Sylhet, Bangladesh. Platelet count/spleen diameter ratio was assessed in all patients and its diagnostic implication was calculated. Upper gastrointestinal endoscopy

Euroasian journal of hepato-gastroenterology2018 Full Text: Link to full Text with Trip Pro

125. Selective screening for atrial fibrillation using multivariable risk models

Selective screening for atrial fibrillation using multivariable risk models 29593077 2018 04 14 1468-201X 2018 Mar 28 Heart (British Cardiac Society) Heart Selective screening for atrial fibrillation using multivariable risk models. heartjnl-2017-312686 10.1136/heartjnl-2017-312686 Atrial fibrillation can lead to stroke if untreated, and identifying those at higher risk is necessary for cost-effective screening for asymptomatic, paroxysmal atrial fibrillation. Age has been proposed to identify (...) those at risk, but risk models may provide better discrimination. This study compares atrial fibrillation risk models with age for screening for atrial fibrillation. Nine atrial fibrillation risk models were compared using the Atherosclerosis Risk in Communities study (11 373 subjects , 60.0±5.7 years old). A new risk model (Screening for Asymptomatic Atrial Fibrillation Events-SAAFE) was created using data collected in the Monitoring Disparities in Chronic Conditions study (3790 subjects, 58.9±15.3

EvidenceUpdates2018

126. Digital breast tomosynthesis (DBT) - asymptomatic women attending breast screening

Digital breast tomosynthesis (DBT) - asymptomatic women attending breast screening 77 1 Health technology description Questions addressed The aim of this evidence note is to establish whether the existing evidence supports the addition of digital breast tomosynthesis (DBT) to the breast screening pathway. The specific questions addressed are: ? In asymptomatic women attending for breast screening, what is the evidence that DBT and full- field digital mammography or synthetic 2D (FFDM or 2SD (...) ), compared to FFDM alone. However, there appears to be no benefit of DBT in detecting ductal carcinoma in situ. ? Several studies report statistically significant reductions in false positives and recall rates when DBT plus FFDM is compared to FFDM alone. However, the magnitude of effect was not consistent across studies. ? In women with dense breasts attending for screening, the addition of DBT to FFDM results in increased breast cancer detection, compared to FFDM alone. ? While the evidence

Evidence Notes from Healthcare Improvement Scotland2018

127. Digital breast tomosynthesis (DBT) - breast screening recall: Advice Statement

Digital breast tomosynthesis (DBT) - breast screening recall: Advice Statement File name: 20180301 Tomosynthesis Recall AS v1.0.docx Version: 1.0 Date: 25 April 2018 Produced by: Page: 1 Review date: Advice Statement 004/18 April 2018 In women who have been recalled from breast screening, what is the clinical and cost effectiveness of digital breast tomosynthesis (DBT) compared with coned views? Advice for NHSScotland Digital breast tomosynthesis (DBT) can be used to aid diagnosis for women who (...) have been recalled from initial breast screening for further assessment. Eight studies have compared DBT with supplementary mammographic views (SMVs, which is the current standard of care). In six studies the diagnostic accuracy was comparable, and in two the diagnostic accuracy of DBT was superior. DBT takes an image of the whole breast. Coned mammographic views require careful positioning of the patient to avoid potential errors resulting from lesions being placed outside the field of compression

SHTG Advice Statements2018

128. Digital breast tomosynthesis (DBT) - asymptomatic women attending breast screening: Advice Statement

Digital breast tomosynthesis (DBT) - asymptomatic women attending breast screening: Advice Statement File name: 20180301 Tomosynthesis Screening AS v1.0.docx Version: 1.0 Date: 25 April 2018 Produced by: Page: 1 Review date: Advice Statement 005/18 April 2018 In asymptomatic women attending for breast screening, what is the clinical and cost effectiveness of digital breast tomosynthesis (DBT) in addition to full-field digital mammography or synthetic 2D (FFDM or S2D) images, compared to FFDM (...) alone? Advice for NHSScotland For asymptomatic women attending routine breast screening, digital breast tomosynthesis (DBT) plus full-field digital mammography (FFDM) is better at detecting invasive cancer compared with FFDM alone. However, when DBT is used in addition to FFDM, this results in a double radiation dose. Furthermore, the cost effectiveness of DBT is unclear; the existing evidence does not evaluate the potential impact of DBT on longer-term outcomes such as interval cancer rates

SHTG Advice Statements2018

129. Prostate Cancer: Screening

Prostate Cancer: Screening USPSTF Final Prostate Screening Recommendations Text Size: Prostate Cancer Screening Final Recommendation Providing clinicians and patients with important information to help guide decisions about prostate cancer screening. The U.S. Preventive Services Task Force (USPSTF or Task Force) has reviewed the evidence on PSA-based screening for prostate cancer and published its final recommendation. The Task Force is deeply committed to a clear and transparent recommendation (...) development process and this final recommendation was informed by comments we received on our draft recommendation from experts, stakeholders and the public. The Task Force recommends men ages 55 to 69 make an individual decision about prostate cancer screening with their clinician. The Task Force recommends against routine screening for men age 70 and older. Final Recommendations Men ages 55–69 For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening

U.S. Preventive Services Task Force2018

130. Colorectal Cancer Screening

Colorectal Cancer Screening Revised 2018 ACR Appropriateness Criteria ® 1 Colorectal Cancer Screening American College of Radiology ACR Appropriateness Criteria ® Colorectal Cancer Screening Variant 1: Colorectal cancer screening. Average-risk individual. Age greater than or equal to 50 years. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double (...) -contrast May Be Appropriate ??? MR colonography May Be Appropriate O X-ray barium enema single-contrast Usually Not Appropriate ??? Variant 2: Colorectal cancer screening. Moderate-risk individual. First-degree family history of cancer or adenoma. Initial screening, then follow-up every 5 years after initial negative screen. Procedure Appropriateness Category Relative Radiation Level CT colonography Usually Appropriate ??? X-ray barium enema double-contrast May Be Appropriate ??? MR colonography May

American College of Radiology2018

131. Los Angeles Motor Scale to Identify Large Vessel Occlusion: Prehospital Validation and Comparison With Other Screens

Los Angeles Motor Scale to Identify Large Vessel Occlusion: Prehospital Validation and Comparison With Other Screens 29459391 2018 03 16 2018 03 16 1524-4628 49 3 2018 03 Stroke Stroke Los Angeles Motor Scale to Identify Large Vessel Occlusion: Prehospital Validation and Comparison With Other Screens. 565-572 10.1161/STROKEAHA.117.019228 Prehospital scales have been developed to identify patients with acute cerebral ischemia (ACI) because of large vessel occlusion (LVO) for direct routing

EvidenceUpdates2018

132. Digital breast tomosynthesis (DBT) - breast screening recall

Digital breast tomosynthesis (DBT) - breast screening recall 76 1 Health technology description Questions addressed ? In women who have been recalled from breast screening for further assessment, what is the evidence that digital breast tomosynthesis (DBT) in place of coned views improves cancer detection? ? How does breast density and type/stage of cancer influence the results? Key points ? Evidence from ten studies suggests that, from a diagnostic perspective, digital breast tomosynthesis (...) (DBT) can be used in place of supplementary mammographic views (SMVs) in women who have been recalled from initial breast screening for further assessment. ? Of eight studies that reported outcomes relating to diagnostic accuracy, six concluded that DBT demonstrated comparable diagnostic accuracy to SMVs. In the remaining two studies, the results suggested that DBT was superior to SMVs in terms of diagnostic accuracy. ? The existing evidence base suggests that the comparable/improved accuracy

Evidence Notes from Healthcare Improvement Scotland2018

133. Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings

Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings E588 CMAJ | MAY 14, 2018 | VOLUME 190 | ISSUE 19 © 2018 Joule Inc. or its licensors I mpaired vision is an important health burden in both devel- oped and developing countries, particularly among older adults. 1 The 2006 Participation and Activity Limitation Survey found that 13% of Canadians aged 75 years and older had a “see- ing limitation,” with 31% described as severe, compared (...) . Comprehensive eye examinations for adults aged 65 years and older are covered by most provincial governments across Canada and are usually free at point of care. It is plausible that screening for impaired vision in primary care settings could be beneficial to individuals who do not recog- nize that they have a vision-related problem or who recognize a problem but do not seek treatment. Scope This guideline presents evidence-based recommendations for pre- venting vision-related functional limitations

CMA Infobase (Canada)2018

134. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report 29374513 2018 04 08 1931-3543 153 4 2018 Apr Chest Chest Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. 954-985 S0012-3692(18)30094-1 10.1016/j.chest.2018.01.016 Low-dose chest CT screening for lung cancer has become a standard of care in the United States in the past few years, in large part due to the results of the National Lung Screening Trial. The benefit and harms of low-dose chest CT screening differ (...) in both frequency and magnitude. The translation of a favorable balance of benefit and harms into practice can be difficult. Here, we update the evidence base for the benefit, harms, and implementation of low radiation dose chest CT screening. We use the updated evidence base to provide recommendations where the evidence allows, and statements based on experience and expert consensus where it does not. Approved panelists developed key questions using the PICO (population, intervention, comparator

EvidenceUpdates2018

135. Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers.

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk of Screen-Detected and Interval Cancers. Background: In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density (...) should be reported instead. Objective: To determine whether breast cancer risk and detection are similar for automated and clinical BI-RADS density measures. Design: Case-control. Setting: San Francisco Mammography Registry and Mayo Clinic. Participants: 1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants. Measurements: Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006

Annals of Internal Medicine2018

136. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis

A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis 29736411 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. 9 10.1038/s41523-018-0062-x Tumor cells disseminate early in tumor development making metastasis-prevention strategies difficult. Identifying proteins that promote the outgrowth of disseminated (...) of potential metastatic drivers was generated, and a high throughput gain-of-function screen was performed in vivo to validate candidates. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified as a metastatic driver. CEACAM5 overproduction enriched for an epithelial gene expression pattern and facilitated tumor outgrowth at metastatic sites. Tissues from patients with metastatic breast cancer confirmed elevated levels of CEACAM5 in lung metastases relative to breast tumors

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

137. Non-Adherence to recommended Pap smear screening guidelines and its associated factors among women attending health clinic in Malaysia

Non-Adherence to recommended Pap smear screening guidelines and its associated factors among women attending health clinic in Malaysia 29796205 2018 11 14 1985-207X 13 1 2018 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia Malays Fam Physician Non-Adherence to recommended Pap smear screening guidelines and its associated factors among women attending health clinic in Malaysia. 10-17 Cervical cancer ranks as the second most frequent cancer among (...) women in Malaysia. Although a cervical screening program has been introduced since 1960s and is provided free of charge in all government health facilities, the coverage and adherence rate to recommendation among Malaysian women remains low. To determine the proportion of non-adherence to Pap smear screening guidelines and its associated factors among women attending a health clinic in Malaysia. A cross sectional study involving 316 women aged 20 to 65 years who had undergone a Pap smear. Universal

Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia2018 Full Text: Link to full Text with Trip Pro

138. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial.

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Background: The long-term effects of sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality in women and men are unclear. Objective: To determine the effectiveness of flexible sigmoidoscopy screening after 15 years of follow-up in women and men. Design: Randomized controlled trial. (ClinicalTrials.gov: NCT00119912 ). Setting: Oslo and Telemark (...) County, Norway. Participants: Adults aged 50 to 64 years at baseline without prior CRC. Intervention: Screening (between 1999 and 2001) with flexible sigmoidoscopy with and without additional fecal blood testing versus no screening. Participants with positive screening results were offered colonoscopy. Measurements: Age-adjusted CRC incidence and mortality stratified by sex. Results: Of 98 678 persons, 20 552 were randomly assigned to screening and 78 126 to no screening. Adherence rates were 64.7

Annals of Internal Medicine2018

139. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis

Early diagnosis from newborn screening maximises survival in severe cystic fibrosis 29692998 2018 11 14 2312-0541 4 2 2018 Apr ERJ open research ERJ Open Res Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. 00109-2017 10.1183/23120541.00109-2017 Newborn screening (NBS) for cystic fibrosis (CF) has been gradually established in several countries, but scant data are available on its long-term effects on survival. Our objective was to evaluate the long-term

ERJ open research2018 Full Text: Link to full Text with Trip Pro

140. Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece

Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece 29636989 2018 11 14 2059-7029 3 3 2018 ESMO open ESMO Open Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT / PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients

ESMO open2018 Full Text: Link to full Text with Trip Pro